During pharma digital intelligence transformation, an awkward phenomenon often appears: companies invest heavily in digital intelligence tools covering everything from customer management to content distribution, but frontline sales reps do not buy in. Some treat the tools like attendance software and fill information perfunctorily. Some simply abandon them and continue using WeChat or notebooks to record customers. Experienced reps may even say the tool is less reliable than their own experience. In fact, sales teams are not resisting digital intelligence itself. They are resisting tools that fail to address their real concerns. Based on the characteristics of pharma and MeDomino's service practice, we have summarized four core reasons and identified the key paths to solving them.
1. Reason One: Profile Data Is Inaccurate, So Tools Lead Reps Astray
For sales reps, the core value of digital intelligence tools is helping them find the right customers and say the right things. If the HCP profile data provided by the tool is inaccurate, it creates more trouble. For example, a tool may tag a physician as focused on oncology targeted therapy, while the physician actually works deeply in chemotherapy. Or the customer's latest academic views and clinical needs may not be updated, causing the rep to communicate with outdated information. This wastes time and may make the physician feel the rep is unprofessional. Over time, reps will feel the tool is less accurate than their own memory and naturally stop using it.
MeDomino's digital intelligence tools solve the data accuracy problem at the source. HCP360 does not integrate only one dimension of basic information. It integrates physicians' academic research updates, clinical diagnosis and treatment habits, past interaction feedback, and other multidimensional content, and can even track changes in physicians' views in real time. For example, if a cardiovascular physician recently begins focusing on optimizing medication for hypertension with diabetes, the tool updates this need in time. More importantly, these data have been validated in implementation at multiple leading pharma companies. The customers and needs identified by sales reps through the tool mostly match real scenarios precisely, preventing detours and encouraging reps to try it proactively.
2. Reason Two: Reps Trust Their Own Experience and Feel Tools Are Detached From Reality
Pharma sales reps, especially senior reps, often have their own survival logic. Which physicians like academic exchange, which customers require long-term maintenance, and which visit timing has a higher success rate are all intuitions accumulated through years in the market. In their view, digital intelligence tools are systems designed by people sitting in offices who do not understand complex frontline scenarios. For example, a tool may recommend visiting a physician on Wednesday afternoon without knowing that the physician has fixed outpatient hours then. Or it may recommend communication topics based on generic logic while ignoring the physician's personal communication habits. Such tools, detached from reality, naturally cannot match the sales rep's experience base.
MeDomino's digital intelligence tools do not apply generic logic to pharma sales scenarios. For example, ACE, the frontline customer engagement assistant, recommends visit timing that avoids busy periods based on physicians' outpatient schedules and academic meeting arrangements. It also intelligently infers familiar topic directions based on public external physician updates and the rep's previous communication records. If the last conversation involved patient adherence, the next recommendation may automatically include related patient management cases. This kind of tool understands frontline scenarios better than generic systems. It does not replace experience; it strengthens experience, helping senior reps feel that the tool helps them work rather than telling them how to work.
3. Reason Three: Operations Are Too Complicated, and Reps Have No Time for Systems
A sales rep's daily rhythm is built on running between sites: two hospitals in the morning, an academic meeting in the afternoon, and WeChat communication with customers in the evening. There is very little time to sit down and organize information. Yet many digital intelligence tools are designed with excessive complexity: more than a dozen fields must be filled on a computer, customer follow-up records must be checked by stage, content, and feedback, and some tools require attachments to be uploaded in a fixed format before submission. For reps, entering information becomes an extra burden. Spending one hour filling in information feels worse than visiting one more customer. Over time, the tool becomes decorative.
MeDomino tools simplify operation from the sales perspective. For example, MeDomino ACE is a mobile application. While waiting at a hospital, reps can quickly check customer updates, record feedback, and even automatically sync interaction traces, such as academic materials sent last week being read, without manual marking. More importantly, the tool automatically fills in some information. Based on HCP360 profiles, it can populate customer department and research direction automatically, reducing repeated entry. This convenience does not delay customer visits. Instead, it saves time, making reps feel that using the tool is worthwhile.
4. Reason Four: Tools Only Record and Do Not Enable Clinical Communication
The core goal of pharma reps is to help physicians recognize the clinical value of a product and then use it reasonably in clinical diagnosis and treatment. But many digital intelligence tools stop at recording: how many follow-ups happened, which materials were sent, and so on. They do not provide practical communication support. For example, they cannot tell what concerns physicians still have about a product, whether around safety data or unclear clinical application scenarios, and they cannot recommend targeted academic content. They may also fail to show how to explain product advantages through the physician's clinical cases. Tools that only keep accounts without helping cannot advance reps' core work, so reps do not rely on them.
The core of MeDomino's digital intelligence tools is communication enablement rather than simple recording. Based on HCP360 demand insight, the tool clearly marks physicians' focus areas and potential concerns about the product. For example, if an oncologist is worried about drug resistance, the tool automatically recommends relevant real-world research data. If the physician recently handled a complex case, it pushes a corresponding product application plan. At the same time, ACE provides reference talking points, not mandatory scripts, such as how to answer physician questions with clinical data and how to explain product advantages based on the physician's diagnosis and treatment habits. Tools that solve practical communication problems and help physicians recognize product value make reps feel that the tool truly moves work forward, so they are willing to use it proactively.
Conclusion: Pharma Reps Do Not Reject Tools; Tools Often Do Not Understand Pharma Reps
Pharma reps' reluctance to use digital intelligence tools is never about resisting change. It is because tools fail to address their core concerns: fear of inaccurate data, fear of being detached from experience, fear of cumbersome operation, and fear that tools do not enable work. MeDomino's practice proves that when tools provide accurate data, understand scenarios, save time, and truly enable communication, pharma reps not only stop resisting, but also actively use them as business helpers. For pharma companies, the key to promoting digital intelligence is not forcing tools onto teams, but designing tools from the rep's perspective. Like MeDomino, every design point, from HCP data to mobile operations and from data security to communication enablement, should fit reps' real needs. Only then can digital intelligence tools truly enter the frontline and become useful support rather than optional burden.
